Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LPR-2: A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

NCT07809256 is registered in ClinicalTrials.gov with EuroCityClinic LLC as lead sponsor.

NCT NCT07809256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07809256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LPR-2: A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
Lead sponsor
EuroCityClinic LLC
Phase
Phase 3
Overall status
Recruiting
Start date
September 30, 2026
Completion date
August 31, 2030
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (non-small cell lung cancer)r